Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$661K Buy
2,625
+225
+9% +$48.4K 0.19% 75
2026
Q1
$522K Hold
2,400
0.16% 74
2025
Q4
$548K Sell
2,400
-446
-16% -$102K 0.17% 76
2025
Q3
$659K Sell
2,846
-38
-1% -$7.74K 0.2% 74
2025
Q2
$535K Buy
2,884
+2
+0.1% +$372 0.17% 74
2025
Q1
$604K Buy
2,882
+3
+0.1% +$583 0.21% 74
2024
Q4
$512K Buy
2,879
+27
+0.9% +$4.96K 0.2% 72
2024
Q3
$563K Buy
2,852
+2
+0.1% +$373 0.22% 69
2024
Q2
$489K Hold
2,850
0.21% 60
2024
Q1
$519K Sell
2,850
-200
-7% -$34.5K 0.22% 56
2023
Q4
$473K Buy
3,050
+250
+9% +$36.4K 0.22% 55
2023
Q3
$417K Hold
2,800
0.22% 50
2023
Q2
$377K Hold
2,800
0.19% 54
2023
Q1
$446K Buy
2,800
+200
+8% +$30.6K 0.26% 47
2022
Q4
$420K Hold
2,600
0.26% 50
2022
Q3
$349K Hold
2,600
0.22% 51
2022
Q2
$398K Hold
2,600
0.26% 48
2022
Q1
$421K Hold
2,600
0.23% 48
2021
Q4
$352K Hold
2,600
0.18% 53
2021
Q3
$280K Buy
2,600
+200
+8% +$22.9K 0.16% 54
2021
Q2
$270K Hold
2,400
0.16% 55
2021
Q1
$260K Hold
2,400
0.17% 55
2020
Q4
$257K Hold
2,400
0.18% 52
2020
Q3
$210K Hold
2,400
0.16% 52
2020
Q2
$236K Buy
+2,400
New +$211K 0.2% 49
2020
Q1
Sell
-2,400
Closed -$212K 36
2019
Q4
$212K Buy
+2,400
New +$199K 0.2% 54

Other funds holding ABBV

Hixon Zuercher's ABBV Position: Q2 2026 in Review

Hixon Zuercher increased its AbbVie (ABBV) stake by 9.4% in Q2 2026, buying an estimated $48.4K and bringing the position to 2,625 shares worth $661K. The position accounts for 0.19% of the portfolio, ranked #75.

Hixon Zuercher first reported a position in ABBV in Q4 2019 and has held it in 26 quarters since. 1,476 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Hixon Zuercher held 2,625 shares of AbbVie worth $661K as of Q2 2026.
  • Hixon Zuercher bought 225 AbbVie shares in Q2 2026, an estimated $48.4K.
  • AbbVie made up 0.19% of Hixon Zuercher's portfolio in Q2 2026, its #75 holding.
  • Hixon Zuercher first reported a position in AbbVie in Q4 2019 and has held it in 26 quarters since.
  • 1,476 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Hixon Zuercher's 13F filing for Q2 2026, filed 20 Jul 2026.